Drug Database
DI

diethylpropion (Regenon retard)

✓ Approved

Bausch Health Companies Inc. · SLC6A2 · 小分子

什么是 diethylpropion?

diethylpropion 是一种小分子,由Bausch Health Companies Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Regenon retard
公司Bausch Health Companies Inc.
药物类别小分子
分子靶点SLC6A2
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

diethylpropion 作用于 1 个分子靶点:

SLC6A2solute carrier family 6 member 2 (NAT1, NET)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

diethylpropion 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersObesity✓ Approved

相关研究文献

PubMedChemical communications (Cambridge, England)2026-11-17

Photochemical dearomatization of indoles via their excited states.

Shen Wen-Jie WJ, Cheng Yuan-Zheng YZ, You Shu-Li SL

Indoline frameworks are widely encountered in bioactive natural products and pharmaceuticals, making their efficient construction an enduring objective in synthetic chemistry. Dearomatization of indoles has emerged as a particularly powerful strategy for accessing these three-dimensional, highly functionalized scaffolds from readily available aromatic precursors. In this context, photochemical activation has opened new avenues for indole dearomatization by harnessing the distinctive reactivity of electronically excited states and enabling bond-forming processes that are often difficult to achieve under conventional thermal conditions. This review highlights recent advances in photochemical dearomatization of indoles, with the discussion organized into intramolecular and intermolecular transformations.

PMID 43041497
阅读全文 →
PubMedHCA healthcare journal of medicine2026-11-17

Pharmacovigilance as an Act of Awareness and Mindfulness.

Silas Mahima M, Toklu Hale Z HZ

Description The term "pharmacovigilance" defines the activities related to the collection, detection, assessment, monitoring, and prevention of adverse reactions due to pharmaceuticals. While it is often framed as a technical and regulatory discipline, it can also be understood through a more reflective lens as a form of mindfulness practice. At its core, pharmacovigilance requires a way of thinking that closely mirrors mindfulness, including sustained attention, openness to uncertainty, and deep awareness of human experience. Viewing pharmacovigilance in this way reframes it not just as a safety mechanism, but as a thoughtful, patient-centered approach to medicine.

PMID 43042117
阅读全文 →
PubMedDrugs2026-11-17

Oveporexton: First Approval.

Brown Michael B MB

Oveporexton (ORZEYFULTM) is an oral selective orexin receptor 2 agonist developed by Takeda Pharmaceuticals Inc. for the treatment of narcolepsy type 1 (NT1). Oveporexton received its first approval in China on 22 July 2026 for the treatment of adolescents aged ≥ 16 years and adults with NT1. Subsequently, oveporexton was approved on 5 August 2026 in the USA and on 24 August 2026 in Japan for adults with NT1. Targeting the underlying orexin deficiency in NT1, oveporexton is the first and only agent approved for the treatment of NT1 addressing the full range of symptoms which define the condition. Additional global filings and phase III clinical trials are ongoing. This article summarizes the milestones in the development of oveporexton leading to this first approval for NT1.

PMID 43040185
阅读全文 →
PubMedBeilstein journal of organic chemistry2026-11-17

Recent advances in chiral aluminum asymmetric catalysis: ligand design, coordination modulation, and structure-activity relationships.

Wen Tianzhe T, Ma Xiaoli X, Pang Ziyuan Z, Yang Xiaobo X et al.

The development of sustainable strategies for asymmetric catalysis remains a central goal in modern synthetic chemistry. Chiral aluminum catalysts, derived from earth-abundant and low-toxicity main-group elements, are emerging as powerful alternatives to precious transition-metal systems. This review systematically surveys two decades of progress in chiral aluminum asymmetric catalysis, with a central focus on the fundamental correlation between rational ligand design, coordination environment tuning at aluminum centers, and the resulting structure-activity/selectivity relationships. We highlight how modular ligand engineering including 1,1'-binaphthyl-2,2'-diol (BINOL), salen, and N-heterocyclic scaffolds enables precise control over aluminum's coordination geometry, Lewis acidity, and chiral microenvironment, delivering high enantio- and regiocontrol across diverse reactions from cycloadditions and asymmetric reductions to C-H functionalization and stereoselective polymerization. Beyond their cost and environmental advantages, these systems showcase unique stereocontrol mechanisms arising from metal-centered chirality and cooperative catalysis. Challenges remain in expanding substrate scope and improving recyclability, but continued innovation promises to establish aluminum catalysis as a frontier platform for the sustainable synthesis of pharmaceuticals, fine chemicals, and functional materials.

PMID 43041906
阅读全文 →
PubMedBMC pharmacology & toxicology2026-11-17

Bioequivalence of two formulations of amitriptyline hydrochloride tablets in healthy Chinese subjects under fasting and fed conditions.

Zhang Jingjing J, Zhai You Y, Kai Jiejing J, Wu Minglan M et al.

The study evaluated the bioequivalence and tolerability of a generic amitriptyline hydrochloride tablet compared to the reference product in healthy Chinese subjects under both fasting and postprandial conditions to support its marketing authorization. A single-center, open-label, randomized, single-dose, two-period, two-sequence crossover study was conducted. Eligible subjects took a single 25 mg dose of the generic or reference product per cycle in random order. Plasma drug concentrations were detected by LC-MS/MS and the bioequivalence of the two formulations was assessed through key pharmacokinetic parameters (Cmax, AUC0-t, and AUC0-∞) of amitriptyline. Adverse events were continuously monitored throughout the trial. The 90% confidence intervals (CIs) for the geometric mean ratios (GMRs) of Cmax, AUC0-t, and AUC0-∞ between the two products fell within the 80-125% range under both fasting and postprandial conditions. Our study indicated that food intake increases systemic exposure to amitriptyline without affecting Tmax. Both formulations were well tolerated, with predominantly mild adverse events and no severe or fatal events. The generic amitriptyline hydrochloride tablets by Changzhou Siyao Pharmaceuticals Co., Ltd. were bioequivalent to the reference formulation by Sandoz Inc. with comparable tolerability. This study was registered at www.chinadrugtrials.org.cn under the registration number CTR20212242 (November 2, 2021).

PMID 43040400
阅读全文 →
PubMedAccounts of chemical research2026-11-17

Cobalt-Catalyzed Asymmetric Reductive Addition to Carbonyls and Related Polarized Unsaturated Bonds.

Wu Xianqing X, Chen Yifeng Y

The catalytic asymmetric construction of carbon-carbon bonds through the addition of carbon-based fragments to carbonyl compounds represents a fundamental transformation in organic synthesis, providing direct access to enantioenriched alcohols and amines that are ubiquitous structural motifs in pharmaceuticals, natural products, and functional molecules. Classical approaches typically rely on stoichiometric organometallic reagents, such as Grignard and organolithium reagents, which suffer from intrinsic limitations including air and moisture sensitivity, restricted functional group compatibility, and the requirement for preformed nucleophilic reagents. These drawbacks often increase synthetic complexity and reduce overall efficiency. Therefore, the development of catalytic asymmetric addition strategies that directly utilize stable and readily available precursors, while avoiding the preparation of sensitive organometallic intermediates, represents a longstanding and highly desirable goal. In this context, reductive coupling of organic halides as latent carbon nucleophiles offers an attractive alternative strategy. The seminal Nozaki-Hiyama-Kishi (NHK) reaction established the feasibility of directly employing organic halides in carbonyl additions; however, its reliance on chromium catalysis and stoichiometric metal reductants limits its practicality and broader application. Despite substantial advances, the development of general catalytic asymmetric methods capable of controlling radical-mediated carbon-carbon bond formation, particularly for constructing sterically congested tetrasubstituted stereocenters and contiguous stereogenic centers, remains a formidable challenge. The pursuit of sustainable and efficient catalytic processes has stimulated growing interest in earth-abundant first-row transition metals, among which cobalt has emerged as a particularly promising catalyst because of its rich single-electron redox chemistry, versatile coordination behavior, and intrinsic ability to mediate radical transformations. In this Account, we summarize our recent efforts in exploiting cobalt catalysis for the asymmetric reductive addition reactions of carbonyl-derived electrophiles and related polarized unsaturated systems with organic halides. This strategy, herein termed cobalt-catalyzed asymmetric reductive addition (CARA), utilizes readily available metal reductants under mild conditions and enables stereocontrolled radical addition processes directed by chiral cobalt complexes. Through this platform, we have developed modular approaches for the synthesis of diverse enantioenriched molecules, including amino acids, alcohols, amides, and sulfinamides, directly from readily available precursors. The development of this catalytic platform is discussed from three perspectives according to the reaction partners: (1) asymmetric reductive addition of simple organohalides for the construction of sterically demanding tetrasubstituted stereocenters; (2) enantioconvergent radical additions of racemic alkyl halides for the formation of contiguous stereogenic centers; and (3) reductive additions to other polarized unsaturated bonds, including isocyanates and sulfinylamines. Through extensive mechanistic investigations and DFT calculations, we have established that these transformations share a common radical addition pathway that is mechanistically distinct from the classical NHK reaction. We anticipate that this Account will stimulate further exploration of catalytic asymmetric reductive additions beyond those of conventional organometallic reagents. Continued development of cobalt-based radical platforms, together with advances in catalyst design and mechanistic understanding, may provide new solutions to longstanding challenges in stereoselective synthesis.

PMID 43042843
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多diethylpropion